Anrukinzumab

Monoclonal antibody for the treatment of asthma

Anrukinzumab

Anrukinzumab is a monoclonal antibody that was developed for the treatment of asthma. It is a humanized antibody that targets the interleukin-13 (IL-13) cytokine, which plays a key role in the inflammatory process associated with asthma.

Mechanism of Action

Anrukinzumab works by binding to IL-13, a cytokine involved in the immune system's response to allergens. IL-13 is known to contribute to the pathophysiology of asthma by promoting inflammation, mucus production, and airway hyperresponsiveness. By inhibiting IL-13, anrukinzumab reduces these effects, potentially alleviating symptoms in patients with asthma.

Development and Clinical Trials

Anrukinzumab was initially developed by MedImmune, a subsidiary of AstraZeneca. The drug underwent several clinical trials to evaluate its safety and efficacy in treating asthma. However, the development of anrukinzumab was eventually discontinued.

During its clinical evaluation, anrukinzumab was administered to patients with moderate to severe asthma to assess its impact on lung function and asthma control. The trials aimed to determine the optimal dosing regimen and to identify any potential side effects associated with the treatment.

Potential Applications

While anrukinzumab was primarily investigated for asthma, the mechanism of targeting IL-13 suggests potential applications in other allergic and inflammatory diseases. IL-13 is implicated in conditions such as atopic dermatitis and chronic rhinosinusitis with nasal polyps, making it a target of interest for various therapeutic interventions.

Discontinuation

Despite the promising mechanism of action, the development of anrukinzumab was halted. The reasons for discontinuation could include insufficient efficacy in clinical trials, safety concerns, or strategic business decisions by the developing company.

Related pages

• Monoclonal antibody therapy
• Asthma
• Interleukin-13
• MedImmune